🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Essen
Clinical trial register · Germany

Clinical Trials in Essen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 41 Essen 26 Ulm 23 Hamburg 22 Dresden 19
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca57 Novartis Pharmaceuticals50 Eli Lilly and Company30 Amgen27 University Hospital, Essen27 Clear sponsor filter
Site location
Berlin41 Essen26 Ulm23 Hamburg22 Dresden19
All 107 locations
Target enrolment
to

Trials with a site in Essen

26 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939HER2-positive Breast Cancer
DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine
Hoffmann-La Roche
Phase 2/3
650
Essen, Dessau, Hamburg, Heidelberg, Koblenz, Langen, München, Paderborn
2026-05-21
Recruiting
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801Breast Cancer
DrugsInavolisib·Ribociclib·Fulvestrant
Hoffmann-La Roche
Phase 2
80
Aachen, Dessau, Essen, Heidelberg, Tübingen
2026-04-07
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 3
1,600
Bad Oeynhausen, Erlangen, Essen, Frankfurt, Gelnhausen, Hamburg, Hof, Köln - Dünnwald
2026-03-23
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Bad Oeynhausen, Erlangen, Essen, Frankfurt, Hamburg, Hof, Köln - Dünnwald, München
2026-03-16
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Halle, Hamburg
2025-10-24
Recruiting
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
NCT07054190Breast Cancer
DrugsGiredestrant·Inavolisib·Ribociclib·Letrozole
Hoffmann-La Roche
Phase 2
120
Berlin, Dresden, Essen, Heidelberg, Paderborn, Schwerin
2025-09-09
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Cologne, Dresden, Essen, Hamburg, Hanover, Heidelberg, Koblenz, Langen
2025-04-09
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Adagrasib·Sotorasib
Hoffmann-La Roche
Phase 3
338
Berlin, Cologne, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Heidelberg, Hemer
2024-09-23
Recruiting
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
NCT06274515Breast Cancer
Hoffmann-La Roche
Phase 4
320
Cologne, Essen, Karlsruhe, Mannheim, Ulm
2024-04-02
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Bamberg, Cologne, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Heidelberg, Homburg/Saar
2023-12-11
Active, closed
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
NCT06128564Duchenne Muscular Dystrophy
Hoffmann-La Roche
Phase 2
13
Essen
2023-11-29
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone
Hoffmann-La Roche
Phase 3
1,130
Berlin, Brandenburg an der Havel, Chemnitz, Cologne, Düsseldorf, Erlangen, Essen, Frankfurt
2023-09-18
Active, closed
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT05852691Breast Cancer
DrugsTobemstomig·Nab-paclitaxel·Pembrolizumab
Hoffmann-La Roche
Phase 2
83
Essen, Langen, Ulm
2023-07-18
Active, closed
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769Chronic Obstructive Pulmonary Disease
DrugAstegolimab
Hoffmann-La Roche
Phase 3
2,000
Augsburg, Bamberg, Bendorf, Berlin, Darmstadt, Deggingen, Essen, Frankfurt
2023-06-28
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862Breast Cancer
DrugsBupropion·Omeprazole·Alpelisib·Inavolisib
Hoffmann-La Roche
Phase 3
420
Aachen, Bielefeld, Essen, Freiburg im Breisgau, Georgsmarienhütte, Göttingen, Hamburg, Hanover
2023-06-07
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
DrugsPhesgo·Giredestrant·Docetaxel·Paclitaxel
Hoffmann-La Roche
Phase 3
922
Bad Nauheim, Bamberg, Essen, Freiburg im Breisgau, Heidelberg, Hildesheim, Homburg/Saar, Langen
2022-07-18
Active, closed
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567Small-Cell Lung Cancer
DrugsLurbinectedin·Tecentriq·Etoposide·Atezolizumab
Hoffmann-La Roche
Phase 3
660
Bad Berka, Berlin, Chemnitz, Essen, Georgsmarienhütte, Großhansdorf, Halle, Immenhausen
2021-11-18
Active, closed
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT04861259Atypical Hemolytic Uremic Syndrome
DrugCrovalimab
Hoffmann-La Roche
Phase 3
83
Cologne, Essen, Hanover
2021-10-22
Active, closed
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
NCT04931342Ovarian Cancer
DrugsCobimetinib·Ipatasertib·Giredestrant·Inavolisib
Hoffmann-La Roche
Phase 2
176
Essen, Mannheim
2021-10-07
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
DrugGiredestrant
Hoffmann-La Roche
Phase 3
4,170
Karlsruhe, Augsburg, Berlin, Chemnitz, Erlangen, Essen, Georgsmarienhütte, Hamburg
2021-08-27
Active, closed
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845Solid Tumors
DrugsCamonsertib·Belvarafenib·Pralsetinib·Divarasib
Hoffmann-La Roche
Phase 2
920
Essen, Göttingen, Heilbronn, Mönchengladbach
2021-01-18
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Palbociclib·Letrozole
Hoffmann-La Roche
Phase 3
992
Berlin, Chemnitz, Dresden, Essen, Georgsmarienhütte, Göttingen, Hamburg, Hanover
2020-10-09
Active, closed
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092Paroxysmal Nocturnal Hemoglobinuria
DrugsCrovalimab·Eculizumab
Hoffmann-La Roche
Phase 3
210
Essen, Ulm
2020-10-08
Active, closed
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499Breast Cancer
DrugsInavolisib·Palbociclib·Fulvestrant
Hoffmann-La Roche
Phase 2/3
325
Berlin, Essen, Heidelberg, Mannheim, Trier, Ulm
2020-01-29
Active, closed
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT03768063Cancer
DrugsEmactuzumab·Rucaparib·Cobimetinib·Vemurafenib
Hoffmann-La Roche
Phase 3
1,000
Ulm, Regensburg, Lübeck, Essen, Freiburg im Breisgau, Gauting, Gera, Immenhausen
2019-02-28
Recruiting
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT03424005Metastatic Breast Cancer
DrugsAtirmociclib·Ipatasertib·Giredestrant·Inavolisib
Hoffmann-La Roche
Phase 1/2
1,132
Erlangen, Essen
2018-03-30
Rows per page Showing 1–26 of 26
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-germany/city/essen

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 26 of those studies with a site in Essen that also match the filters currently applied.

How many clinical trials are recruiting in Essen?

10 of the 26 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 16 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Essen), 26 studies
PhaseStudiesRecruitingShare
Phase 316561.5%
Phase 26223.1%
Phase 2/3217.7%
Phase 1/2113.8%
Phase 4113.8%

Most active sponsors

Lead sponsors with the most studies (Essen)
Lead sponsorStudiesRecruiting
Hoffmann-La Roche2610
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.